

**Amendments to the Claims:**

Please amend claims 1, 3, 6, 7, 10-13, 34-36 and 38-41, cancel claims 2, 4-5, and 14-33, and add new claims 42-48. This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1           1 (currently amended): A method for ~~modulating~~ reducing expression of a  
2 mammalian SREBP-1 gene by administering ~~a modulator compound that promotes or an~~  
3 antagonist of LXR $\alpha$  that inhibits LXR $\alpha$ -mediated expression of the SREBP-1 gene to a cell that  
4 comprises an SREBP-1 gene and an LXR $\alpha$  polypeptide, wherein said antagonist is an oxysterol.

1           2 (canceled).

1           3 (currently amended): The method of claim 1, wherein the ~~modulator~~  
2 ~~compound promotes or antagonist~~ inhibits LXR $\alpha$ -mediated expression of the SREBP-1c  
3 transcript.

1           4 (canceled).

1           5 (canceled).

1           6 (currently amended): The method of claim ~~5~~ 1, wherein the cell further  
2 comprises one or more genes that encode an enzyme involved in fatty acid and triglyceride  
3 metabolism and contacting the cell with the ~~modulator compound~~ antagonist inhibits expression  
4 of one or more of the genes that encode an enzyme involved in fatty acid and triglyceride  
5 metabolism.

1           7 (currently amended): The method of claim ~~1~~ 6, wherein the enzyme involved  
2 in fatty acid and triglyceride metabolism is selected from the group consisting of fatty acid  
3 synthase, acetyl CoA carboxylase, steroyl CoA desaturase, and lipoprotein lipase.

1           8 (original): The method of claim 1, wherein the cell is in a mammal.

1           9 (original): The method of claim 8, wherein the mammal is a human.

1           10 (currently amended): The method of claim 8, wherein ~~the modulator~~  
2 ~~compound is an antagonist of LXR $\alpha$  and~~ triglyceride levels in the mammal are reduced.

1           11 (currently amended): The method of claim 8, wherein ~~the modulator~~  
2 ~~compound is an antagonist of LXR $\alpha$  and~~ insulin levels in the mammal are reduced.

1           12 (currently amended): A method of modulating triglyceride levels in a  
2 mammal, the method comprising administering to the mammal an effective amount of a  
3 modulator compound that comprises at least one of LXR $\alpha$  antagonist and LXR $\alpha$  agonist activity  
4 that promotes or inhibits LXR $\alpha$ -mediated expression of an SREBP-1 gene in cells of the  
5 mammal, wherein the modulator compound is an oxysterol.

1           13 (currently amended): The method of claim 12, wherein the mammal is a  
2 human.

1           14-33 (canceled)

1           34 (currently amended): A method for ameliorating a condition associated with  
2 ~~abnormal~~ abnormally high SREBP-1 expression in a mammal, the method comprising  
3 administering to the mammal a therapeutically effective amount of a LXR $\alpha$  antagonist, wherein  
4 said antagonist is an oxysterol.

1           35 (currently amended): The method of claim 34, wherein the condition  
2 associated with ~~abnormal~~ abnormally high SREBP-1 expression is hypertriglyceridemia.

1           36 (currently amended): The method of claim 34, wherein the condition  
2 associated with ~~abnormal~~ abnormally high SREBP-1 expression is lipodystrophy.

1                   37 (original): The method of claim 36, wherein the lipodystrophy is congenital  
2 generalized lipodystrophy.

1                   38 (currently amended): The method of claim 34, wherein the condition  
2 associated with ~~abnormal~~ abnormally high SREBP-1 expression is insulin resistance.

1                   39 (currently amended): The method of claim 34, wherein the condition  
2 associated with ~~abnormal~~ abnormally high SREBP-1 expression is an elevated plasma insulin  
3 level.

1                   40 (currently amended): The method of claim 34, wherein the condition  
2 associated with ~~abnormal~~ abnormally high SREBP-1 expression is hyperglycemia and/or  
3 diabetes mellitus.

1                   41 (currently amended): The method of claim 34, wherein the condition  
2 associated with ~~abnormal~~ abnormally high SREBP-1 expression is a syndrome associated with  
3 treatment of AIDS by administration of an HIV protease inhibitor, which syndrome is  
4 characterized by one or more of lipodystrophy, insulin resistance and hyperlipidemia.

1                   42. (new): The method of claim 34, wherein the condition associated with  
2 abnormally high SREBP-1 expression is pancreatitis.

1                   43. (new): The method of claim 12, wherein the modulator compound is an  
2 agonist of LXR $\alpha$  and promotes LXR $\alpha$ -mediated expression of the SREBP-1 gene.

1                   44 (new): The method of claim 12, wherein the modulator compound promotes  
2 or inhibits LXR $\alpha$ -mediated expression of the SREBP-1c transcript.

1                   45 (new): The method of claim 43, wherein the modulator compound is 24,25-  
2 epoxycholesterol.

1                   46 (new): The method of claim 12, wherein the modulator compound is an  
2 antagonist of LXR $\alpha$  and inhibits LXR $\alpha$ -mediated expression of the SREBP-1 gene.

1                   47. (new): A method of increasing triglyceride levels in a mammal, the method  
2 comprising administering to the mammal an effective amount of an agonist of LXR $\alpha$  that  
3 promotes LXR $\alpha$ -mediated expression of an SREBP-1 gene in cells of the mammal.

1                   48. (new): The method of claim 47, wherein the agonist is selected from the  
2 group consisting of an oxysterol, *N*-methyl-*N*-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-  
3 ethyl)-phenyl]-benzenesulfonamide (T0314407), *N*-(2,2,2-trifluoro-ethyl)-*N*-[4-(2,2,2-trifluoro-1-  
4 hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide (T0901317), and mixtures  
5 thereof.

1                   49. (new): A method of decreasing triglyceride levels in a mammal, the method  
2 comprising administering to the mammal an effective amount of an antagonist of LXR $\alpha$  that  
3 inhibits LXR $\alpha$ -mediated expression of an SREBP-1 gene in cells of the mammal, wherein the  
4 modulator compound is an oxysterol.